The Latest Cardiac and Vascular News
– FDA Fast Track designation facilitates the development of potential new therapies that treat serious conditions and fulfill an unmet medical need – This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute myocardial infarction, more commonly known as a […]
Heart valve disease is a common, serious but treatable condition, often associated with ageing, yet only 3% of older Canadians are aware of its most common formi Survey shows huge variance across Canada in use of simple stethoscope check to pick up characteristic ‘murmur’ of the heart valves, from 60% […]
– FDA Agreement to Move Directly into Phase 3 – – FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG – BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused […]
SEATTLE–(BUSINESS WIRE)–Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) analysis. Curi’s Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like […]
NEW YORK, Sept. 14, 2020 /PRNewswire/ — NYU Langone’s Transplant Institute and Hassenfeld Children’s Hospital have launched a new pediatric heart failure and transplantation program, bolstering the institution’s comprehensive offering of solid organ and blood and bone marrow transplants, as well as expanding regional access to this specialized level of care for children. The program is led […]
– Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients – – Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response […]
TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor; Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications; A milestone in the further development of TOTUM-070, in the search for commercial partnerships […]
HANGZHOU, China, Sept. 10, 2020 /PRNewswire/ — The leading transcatheter heart valve medical device player in China – Venus Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2500) and Jilin Changchun Haoyue Halal Meat Co., Ltd (“Haoyue Group“), are pleased to announce the establishment of a joint venture company, Venus Haoyue Medtech […]
EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment […]
Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation DUBLIN, Sept. 9, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility […]
